Oncology CNS Focus NextGen Sciences targets oncology and CNS biomarker markets, presenting an opportunity to upsell specialized protein assay development and qualification services to pharma and biotech clients prioritizing these therapeutic areas.

Biomarker Diagnostics Aspiration The company aims to establish a diagnostic business stream for early diagnosis, prognosis and patient stratification, signaling potential sales of biomarker panels, companion diagnostics collaborations, and translational research services.

Clinical Partnerships With experience serving 16 of the top 20 pharma/biotech firms and various academic clients, there is strong traction for multi-site studies, collaboration agreements, and extended CRO services to expand market access.

Growth via Services As a growing CRO leveraging mass spectrometry for quantitative protein assays, NextGen can scale services around assay development, qualification, and discovery collaborations to capture share in pharma pipelines and biomarker qualification programs.

Financial & Scale Fit Revenue in the $1M–$10M band with a lean team (11–50 employees) suggests a boutique, high-value partner; targeting mid-to-large biotech and niche pharma firms seeking rapid, specialized biomarker solutions could yield high-value engagements.